Cassava Sciences (NASDAQ:SAVA) 주식

Cassava Sciences

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Long Ideas

Short Ideas

Trading Ideas

$BTC

AMZN

MSTR

PLTR

RIVN

SAVA

TSLA

벤징가는 지난주 많은 투자자들이 선호하는 주식들의 전망을 조사한 결과를 바탕으로, 다음과  같이 주요 뉴스 몇 가지를 요약했다. 다우 지수가 1.4% 상승하여 11월 상승률을 7.5%로 끌어올린 반면, S&amp;P 500과 나스닥 종합지수는 각각 1.1% 상승하여 월간 상승률이 각각 5%와 6%를 넘어서며 다우와 S&amp;P 500의 2024년 최고의 월간 실적을 기록했다.

벤징가 불스 앤 베어스: 아마존, 테슬라, 리비안, 팔란티어 그리고 도지코인

News

Markets

월요일(25일) 미국 증시는  S&amp;P 500 지수와 다우존스 지수가 사상 최고치를 경신하며 역사적인 하루를 보냈다. 러셀 2000 지수 역시 글로벌 지정학적 긴장 완화, 대선 이후 강세 모멘텀, 계절적 호재에 힘입어 사상 최고치를 기록했다. 하지만 비트코인과 금은 하락세를 보였다.

월요일 주목받은 주식: 카사바 사이언스, 줌, 콜스, 리비안 및 테슬라

Biotech

Large Cap

Topics

Movers

General

AVXL

CHWY

SOFI

게임스탑(NYSE:GME), 소파이 테크놀로지스(NASDAQ:SOFI), 테슬라(NASDAQ:TSLA), 카사바 사이언스(NASDAQ:SAVA) 및 아나벡스 라이프 사이언스(NASDAQ:AVXL)는 금요일 스탁트위츠(Stocktwits)에서 가장 많이 언급된 상위 5개 종목이다. 무엇이 소매 투자자들의 주목을 받았는지 살펴보겠다.

금요일 상위 5개 트렌드 주식: 게임스탑, 소파이, 테슬라, 카사바 및 아나벡스에 대한 소식은?

Cassava Sciences Inc

Cassava Sciences Inc Warrants (15/11/2024)

SAVANNAH GOLDFIELDS LTD by SAVANNAH GOLDFIELDS LTD

SAVANNAH ENERGY PLC by Savannah Energy Plc

Savannah Energy PLC

SAVANNAH RESOURCES PLC by SAVANNAH RESOURCES PLC

Savannah Resources PLC

Savara Inc

Savaria Corp

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) with a Buy and maintains $10 price target.

Price Target

Reiteration

Analyst Ratings

RAPT

HC Wainwright & Co. Reiterates Buy on RAPT Therapeutics, Maintains $10 Price Target

Diversified Energy Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEC#NYSE">DEC</a>), FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>), and TESIAC disclosed a strategic partnership to meet the growing <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44213155/diversified-energy-fuelcell-energy-and-tesiac-collaborate-to-form-an-acquisition-and-development-c" rel="noreferrer noopener">energy demands of data centers</a>.
The collaboration plans to supply up to 360 megawatts of electricity across three locations in Virginia, West Virginia, and Kentucky.
The partnership will form an Acquisition and Development Company (ADC) to deliver reliable, cost-efficient, net-zero power from natural gas and captured coal mine methane (CMM) for data centers.
Leveraging local gas production, fuel cell technology, and infrastructure financing, the collaboration aims to create a scalable, sustainable energy solution to meet growing data center demands.
This partnership aims to develop a decentralized, high-performance, and sustainable energy solution to support the growing power demands of AI and high-performance GPU-driven data centers.
Utilizing U.S.-made technology and materials, the initiative could generate hundreds of well-paying jobs across construction, operations, maintenance, and engineering while fostering innovation in the data center industry and other high-energy sectors.
The projects aim to deliver abundant, reliable power to data centers within two years, ensuring continuous, scalable energy supply and uptime stability amid market fluctuations.
Brad Gray, President and Chief Financial Officer of Diversified Energy, said,&nbsp;&#8221;The market demand for the type of reliable, quickly dispatchable power that only natural gas can deliver is incredibly strong, and we&#8217;re excited about the potential of this partnership to deploy Diversified Energy-produced natural gas and coal mine methane (CMM) and pair it with Fuel Cell&#8217;s advanced industrial-scale technology to create an efficient, cost-effective, environmentally sound solution for the next generation power needs of data centers.&#8221;
Jason Few, President and CEO of FuelCell Energy, stated, &#8221;We believe the future of AI and other high-performance computing will require an abundant supply of clean, reliable, and locally generated power, ensuring that data centers can operate with maximum efficiency and sustainability.&#8221;
Karen Morgan, Managing Partner at TESIAC, stated, &#8220;We anticipate there will be multiple benefits for communities from this collaboration. Stabilizing the energy supply, while capturing methane emissions, turns an environmental challenge into an economic growth opportunity, creating steady job growth as a result of bringing the supply chain closer to the source of power and the end user.&#8221;
In January, Diversified Energy plans to acquire&nbsp;Maverick Natural Resources, an EIG portfolio company,&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/25/01/43232223/diversified-energy-to-close-1-275-billion-acquisition-of-maverick-strengthening-position-in-anadarko-and-permian-basins" rel="noreferrer noopener">for around $1.275 billion</a>.
Price Action: DEC shares closed up 0.89% at $11.28 on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/44213860" target="_blank" rel="noreferrer noopener">TSMC Rides AI Wave: Sales Surge 39% In First 2 Months Of 2025 On Higher Demand</a></li>
</ul>
Photo via Shutterstock.

Contracts

Small Cap

FCEL

FuelCell Energy, Diversified Energy, TESIAC Join Forces To Meet Growing AI Power Demands

William Blair analyst Ryan Merkel upgrades W.W. Grainger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) from Market Perform to Outperform.

Upgrades

William Blair Upgrades W.W. Grainger to Outperform

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) with a Buy and maintains $10 price target.

AQST

HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target

Immunome, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNM#NASDAQ">IMNM</a>), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that the first patient has been dosed in the Phase 1, first-in-human trial of IM-1021, a ROR1-targeted ADC.
"Immunome is developing differentiated ADCs that we believe can greatly benefit cancer patients," said Bob Lechleider, M.D., Chief Medical Officer at Immunome. "The dosing of our first patient with IM-1021 advances that mission, as we work to establish safety and explore efficacy of IM-1021 in patients with high unmet need in B-cell lymphomas and solid tumors."
IM-1021 is an optimized, ROR1-targeted ADC that incorporates Immunome's proprietary TOP1 inhibitor, HC74. The Phase 1 trial is an open-label, multicenter dose escalation and expansion study designed to determine the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of IM-1021. The study is expected to include participants with advanced B-cell lymphomas and advanced solid tumors.

IMNM

Immunome Doses First Patient in Trial for New Cancer-Fighting Drug IM-1021

William Blair analyst Ryan Merkel upgrades Fastenal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) from Market Perform to Outperform.

FAST

William Blair Upgrades Fastenal to Outperform

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) with a Buy and raises the price target from $8 to $11.

CDXC

HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $11

The United States is considering a potential partnership with the Democratic Republic of Congo (DRC) to secure access to <a target="_blank" href="https://www.benzinga.com/markets/commodities" rel="noreferrer noopener">critical minerals</a>, following discussions initiated by a senior Congolese official.
According <a target="_blank" href="https://www.ft.com/content/3f638e29-4790-4a10-b5b7-a79f9ef55491" rel="noreferrer noopener">to</a> the Financial Times, the DRC proposed a minerals-for-security deal, offering valuable resources for military support to address ongoing conflict in the region, particularly with the M23 rebel group who seized control of eastern parts of the North Kivu province.
President Felix Tshisekedi recently hinted at the deal in an interview for the New York Times, while a State Department spokesperson confirmed the situation.
"The DRC is endowed with a significant share of the world's critical minerals required for advanced technologies. The United States is open to discussing partnerships in this sector that align with the Trump administration's America First agenda," they said.
The DRC has significant mineral resources, including cobalt, lithium, copper, and tantalum. It is a global leader in cobalt production, supplying over 70% of the metal's production. Cobalt is essential for electric vehicle batteries and renewable energy technologies.
Still, its status has been problematic, as declining prices forced foreign operators like the Chinese miner MMG to <a target="_blank" href="https://www.benzinga.com/news/global/25/03/44168899/mmg-pauses-cobalt-production-in-congo-as-price-hits-historic-lows" rel="noreferrer noopener">pause production</a>. Meanwhile, the government implemented a four-month export ban to stabilize the oversupplied market.
On top of illegal mining and smuggling, escalating armed conflicts are likely the main catalyst for ongoing talks with Washington. The M23 rebel group, allegedly backed by neighboring Rwanda, has seized significant territory in the eastern part of the country, threatening mineral-rich territory.
Since the conflict has also drawn in neighboring Burundi and Uganda, the situation risks escalating into a full-scale regional conflict.
While a deal with the U.S. would stabilize the region, in exchange, the U.S. would gain access to critical minerals and reduce reliance on Chinese-dominated supply chains.
China controls most of the DRC's mining sector through the state-owned MMG. Washington could seize this opportunity to reduce Beijing's influence while securing resources for its industrial needs.
Yet, a deal between Washington and Kinhasa is a tall order. The political climate in Kinshasa is volatile, and past foreign mining agreements in the DRC have faced criticism over transparency issues.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44188315/germany-could-meet-its-lithium-needs-from-domestic-sources-study-says" target="_blank" rel="noreferrer noopener">Germany Could Meet Its Lithium Needs From Domestic Sources, Study Says</a></li>
</ul>
Photo via Shutterstock

Government

Commodities

Politics

BATT

CARZ

DRIV

IDRV

KARS

DR Congo Explores Minerals-For-Security Deal With The US

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) with a Buy and maintains $19 price target.

ALMS

HC Wainwright & Co. Reiterates Buy on Alumis, Maintains $19 Price Target

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) with a Buy and maintains $8 price target.

HC Wainwright & Co. Reiterates Buy on Unity Biotechnology, Maintains $8 Price Target

The acquisition marks a significant step in NETCLASS' strategy to expand its market across Asia. It provides the Company with a new operational center in Tokyo, Japan, and signifies the Company's dedication to its long-term plan through enhancing its software development capability, improving the quality of existing products, and diversifying its customer base

NTCL

NETCLASS TECHNOLOGY Enters Japan Market Via Strategic Acquisition Of Createsolutions; Eyes Regional Growth And Innovation

Today, during TMC's 2025 Annual Meeting &amp; Transportation Technology Exhibition, <a href="https://www.globenewswire.com/Tracker?data=oIBFlhCGj2iyGabzNvH-QtyhXc01zojN8oJuOF7d4khNcCYSVMrKSahqpheVBRVrOBV8ah7WHFnXKLTQJS6ODuT6rH1mclWPco71lhbyDaDAAn69LrrIKnMFs2hsjI20yxrpHrNKmxreMvlYbcPO-oieXFvpAsat3VPHRU7V4jvkIU2qZIMVNJ00iHMDyLADb13xqQhrUWHPtd1ORaAp25AKvE6YIxr4dbbyGx9Qtc5sUtkwcYPFVC-cgVwlPNLwPpINCtaUct3ZJtImL0Or0zzr8hVBjtLYfjHaWM0Nx8R2x5wLpDul2ePtqXN2uFZYAutho7AHfx5vGat2_46S1Ae3YYgRTa2jqdqqDNZvhhq2p35254qxfc2DE211stlDK4XRRD0kWV3DWbhnNaDLEw==">Dragonfly Energy Holdings Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) ("Dragonfly Energy" or the "Company"), an industry leader in energy storage and battery technology, unveiled the new Battle Born&#xAE; DualFlow Power Pack. This innovative lithium power system is designed to eliminate idle time and alleviate strain on starter batteries by providing dedicated power for hotel loads in long haul trucks. Engineered for universal compatibility, the DualFlow Power Pack installs inside the sleeper cab under the bunk without any modifications to existing systems.
The DualFlow Power Pack powers auxiliary loads while the truck is parked by removing cycles from the starter batteries and extending the lifespan while reducing unnecessary engine starts. Once the truck is back in motion, it recharges using Wakespeed&#xAE; Charge Control Technology, making use of available energy without additional fuel consumption. Designed for Heavy-Duty Trucking fleets and owner-operators with sleeper cabs, it is particularly well-suited for fleets that do not use auxiliary air conditioners. With a low price point and an ROI well under a year, the Company believes fleets can quickly recover their investment and witness significant real-world savings in fuel costs, battery replacements, and maintenance.

DFLI

Dragonfly Energy Unveils DualFlow Power Pack to Cut Truck Idle Time, Save Fuel

This is inclusive of non-recurring first-of-a-kind, Project Permian site-specific and owner costs. Provided the successful value engineering process, the project would come online no earlier than 2029.

NPWR

Net Power Now Estimates Project Permian's Total Installed Cost To Be Between $1.7B And $2.0B

Citigroup analyst Spiro Dounis upgrades Pembina Pipeline (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PPL#TSX">PPL</a>) from Neutral to Buy and announces C$63 price target.

TSX:PPL

Citigroup Upgrades Pembina Pipeline to Buy, Announces C$63 Price Target

CYTK

Cytokinetics Said Maintain Expectation For Differentiated Label & Risk Mitigation Profile For Aficamten, If Approved By FDA

<ul>
<li>ARO-C3 achieved deep and sustained reductions in alternative pathway complement activity and proteinuria.</li>
<li>Mean sustained reductions in C3 of ≥87%, AH50 of ≥76%, Wieslab AP of ≥89% through week 24.</li>
<li>Mean reduction in spot urine protein-to-creatinine ratio (UPCR) of 41% by week 24</li>
</ul>

Health Care

ARWR

Arrowhead Pharmaceuticals Announced Topline Results From Part 2 Of A Phase 1/2 Study Of ARO-C3 To Reduce Liver Production Of Complement Component 3 As A Potential Therapy For Various Complement Mediated Diseases

Management

OPRX

OptimizeRx Corporation Appoints Stephen Silvestro as Chief Executive Officer, Effective Mar. 10

<a href="https://www.globenewswire.com/Tracker?data=R6VVCCZIhiwgUK0Su5g-03QsiEEun8cdd7B68fBQab3f-o8XagXSGpWRxYbe3KXmnxg4V22ck5WnzOKfP9JaPJm6lt1rWMx8tCLg6zAAzG4=">Plus Therapeutics</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) (the "Company" or "Plus Therapeutics"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that on March 7, 2025 the Company received confirmation from Nasdaq that the Company has regained compliance with Nasdaq's minimum stockholders' equity requirement. The Company's common stock will continue to be listed and traded on The Nasdaq Capital Market.

Regulations

PSTV

Plus Therapeutics Regains Nasdaq Compliance, Keeps Stock Listed on Capital Market

BEKE

KE Holdings Class A Ordinary Shares Traded On Hong Kong Stock Exchange Have Been Included In Hong Kong Stock Connect And Shenzhen-Hong Kong Stock Connect Programs

Net Power Says It Closed 2024 With $533M In Cash, Cash Equivalents, And Investments, Down From $580M Last Quarter

Legal

Press Releases

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 10, 2025 in Cassava Sciences, Inc. Lawsuit – SAVA

CASSAVA SCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA

SAVA Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Cassava Sciences, Inc. (SAVA) Investors of Filing Deadline in Class Action Lawsuit

Lead Plaintiff Deadline on February 10, 2025 for SAVA Investors - Kessler Topaz Meltzer & Check, LLP Encourages Investors with Losses to Contact the Firm

SAVA DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Cassava Sciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important February 10 Deadline in Securities Class Action – SAVA

Cassava Sciences, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before February 10, 2025 to Discuss Your Rights - SAVA

Comments

Cassava Sciences

뉴스

파트너 / 기고자

벤징가 글로벌